Reuters logo
8 months ago
BRIEF-Sage Therapeutics starts Phase 2 clinical development for SAGE-217 in movement disorders
December 13, 2016 / 12:17 PM / 8 months ago

BRIEF-Sage Therapeutics starts Phase 2 clinical development for SAGE-217 in movement disorders

Dec 13 (Reuters) - Sage Therapeutics Inc

* Essential tremor study is anticipated to report results in second half of 2017

* Sage Therapeutics announces initiation of Phase 2 clinical development for SAGE-217 in movement disorders

* Sage Therapeutics - top-line results from part a open-label study in Parkinson's disease are expected in first half of 2017

* Also plans to initiate Phase 2 clinical trials of SAGE-217 in two mood disorders Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below